Table 3 Sensitivity analysis results adding post-trandomisation covariates.

From: Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma

Parameter

Model 1

Model 2

HR

p-value

95% CI

HR

p-value

95% CI

Lenvatinib

0.760

<0.001

0.652

0.887

0.765

0.001

0.656

0.892

Alpha fetoprotein >200 ng/ml

1.696

<0.001

1.453

1.980

1.685

<0.001

1.443

1.968

Child-Pugh Score

1.590

<0.001

1.338

1.890

1.579

<0.001

1.328

1.878

EHS

1.248

0.038

1.013

1.538

1.258

0.031

1.021

1.549

Liver disease involvement

2.371

<0.001

1.693

3.319

2.369

<0.001

1.692

3.317

MPVI

1.299

0.004

1.085

1.556

1.309

0.003

1.094

1.567

Hepatitis B

1.222

0.010

1.049

1.422

1.219

0.011

1.047

1.419

Bone disease involvement

1.561

<0.001

1.220

1.997

1.541

0.001

1.205

1.970

Lung disease involvement

1.358

0.002

1.118

1.649

1.358

0.002

1.119

1.649

Other disease involvement

1.229

0.045

1.005

1.504

1.204

0.071

0.984

1.474

Post-treatment therapy

0.599

<0.001

0.514

0.699

–

–

–

–

Post-treatment medication

–

–

–

–

0.681

<0.001

0.579

0.802

Post-treatment procedure

–

–

–

–

0.690

<0.001

0.569

0.835

AIC

8402

   

8400

   
  1. AIC Akaike information criterion, EHS extrahepatic spread, HR hazard ratio for overall survival, MVPI macroscopic portal vein invasion.
Back to article page